Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary preven...

Full description

Bibliographic Details
Main Author:	V. V. Kashtalap
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2022-12-01
Series:	Российский кардиологический журнал
Subjects:	hypertension dyslipidemia cardiovascular risk comorbidity fixeddose combinations polypills
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/5285

Similar Items

Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?
by: Z. D. Kobalava, et al.
Published: (2020-11-01)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
by: Lopez-Lopez JP, et al.
Published: (2023-09-01)

Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management
by: Keisuke Narita, et al.
Published: (2023-11-01)

LIPITENSION : Interplay between dyslipidemia and hypertension
by: Jamshed J Dalal, et al.
Published: (2012-01-01)

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico
by: Enrique Gómez-Álvarez, et al.
Published: (2020-08-01)

Potential of combination therapy in patients with hypertension and dyslipidemia
by: T. V. Gorokhova, et al.
Published: (2022-08-01)

Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases
by: Ruth Webster, et al.
Published: (2020-08-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
by: Samaneh Noroozi, et al.
Published: (2021-04-01)

Polypill" conception in modern cardiology
by: I E Chazova, et al.
Published: (2018-12-01)

Obesity in dyslipidemia and hypertension: A study among young adults of Delhi/NCR
by: Sumit Mishra, et al.
Published: (2023-07-01)

Increment of the effectiveness of treating hypertension and dyslipidemia using a triple fixed-dose combination and the vascular age concept
by: O. V. Tsygankova, et al.
Published: (2020-09-01)

Evaluation of the polypill therapy effectiveness in patients with arterial hypertension and dyslipidemia who underwent COVID-19
by: V.E. Oleynikov, et al.
Published: (2024-03-01)

Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020
by: Catherine G. Derington, et al.
Published: (2023-06-01)

Association of healthy lifestyles on the risk of hypertension, type 2 diabetes mellitus, and their comorbidity among subjects with dyslipidemia
by: Peng Hu, et al.
Published: (2022-09-01)

Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension
by: Anthony Rodgers, et al.
Published: (2024-02-01)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
by: Maciej Banach, et al.
Published: (2023-11-01)

Dynamic changing smoking habits and cardiovascular events in patients newly diagnosed with hypertension, diabetes, or dyslipidemia: a national cohort study
by: Shinjeong Song, et al.
Published: (2023-06-01)

Efficacy and Safety of a Single-Pill Combination of Atorvastatin/Amlodipine in Patients with Arterial Hypertension and Dyslipidemia
by: Stefan Naydenov Naydenov, et al.
Published: (2018-01-01)

Pleiotropic Effects of Losartan in Hypertensive Patients with Dyslipidemia
by: Sivakumar Sivasubramaniam, et al.
Published: (2017-09-01)

The Associations between Liver Enzymes and Cardiovascular Risk Factors in Adults with Mild Dyslipidemia
by: Eun-Ock Park, et al.
Published: (2020-04-01)

Risk and dyslipidemia
by: Sadi Güleç
Published: (2018-10-01)

ADVANTAGES AND NOVELTY OF CLINICAL APPLICATION OF THE TRIPLE COMBINATION FOR ARTERIAL HYPERTENSION WITH DYSLIPIDEMIA: ACE INHIBITOR PERINDOPRIL WITH ROSUVASTATIN AND INDAPAMIDE
by: M. L. Maksimov, et al.
Published: (2017-08-01)

Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
by: D. Yu. Sedykh, et al.
Published: (2022-07-01)

TREATMENT OF ARTERIAL HYPERTENSION AND DYSLIPIDEMIA IN REAL CLINICAL PRACTICE. THE SYNERGY STUDY. Part 2
by: O. M. Drapkina, et al.
Published: (2017-07-01)

Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial
by: Chan Joo Lee, et al.
Published: (2024-03-01)

FREQUENCY OF DYSLIPIDEMIA IN PATIENTS OF TYPE 2 DIABETES WITH HYPERTENSION IN SOUTHERN PUNJAB TERTIARY CARE HOSPITAL
by: Asad Raza, et al.
Published: (2018-08-01)

Evaluation of Cardiovascular Risks and Dyslipidemia in HIV-positive Patients
by: Banu Karaca, et al.
Published: (2023-09-01)

Self-reported hypertension, dyslipidemia and hyperuricemia management by Italian Internal Medicine Units: a national survey of the FADOI Study Group in Cardiovascular Medicine
by: Alberto Mazza, et al.
Published: (2017-11-01)

Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial
by: José M. Mostaza, et al.
Published: (2022-12-01)

The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
by: Lilian Grigorian-Shamagian, et al.
Published: (2023-08-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
by: Lilian Grigorian-Shamagian, et al.
Published: (2021-08-01)

The Concept of the Polypill in the Prevention of Cardiovascular Disease
by: Brandon Wiley, et al.
Published: (2014-04-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
by: Siddharth Birla, et al.
Published: (2023-09-01)

Patient journey for hypertension and dyslipidemia in Saudi Arabia: highlighting the evidence gaps
by: Ashraf Amir, et al.
Published: (2023-07-01)

The combined effect of serum cystatin C and dyslipidemia on hypertension in a large health check-up population in China
by: Jun Ma, et al.
Published: (2019-11-01)

Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review
by: Ana Baumgartner, et al.
Published: (2020-02-01)

A semi-systematic review on hypertension and dyslipidemia care in Egypt—highlighting evidence gaps and recommendations for better patient outcomes
by: Ashraf Reda, et al.
Published: (2021-12-01)

Association of Dyslipidemia and Comorbidities with Risk Factors Among Diabetic Patients: A Retrospective Analysis
by: Gazzaz ZJ, et al.
Published: (2020-03-01)

Nutrients Intake in Individuals with Hypertension, Dyslipidemia, and Diabetes: An Italian Survey
by: Cecilia Guastadisegni, et al.
Published: (2020-03-01)

PLATELET HEMOSTASIS DYNAMICS IN SIMVASTATINTREATED PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
by: I. N. Medvedev, et al.
Published: (2010-02-01)